科创板生物医药行业集体业绩说明会启幕

Core Insights - The 2024 annual report performance briefing series for the biopharmaceutical industry on the Sci-Tech Innovation Board has commenced, focusing on new drug development, overseas business expansion, and future development strategies as key investor concerns [1] Group 1: New Drug Development - The company plans to increase its R&D investment, with a total of 70.41 million yuan in 2024, representing a year-on-year increase of 26.25%. The company is conducting Phase III clinical trials for its antidepressant JJH201501 and Phase IIa trials for its anti-tumor drug JJH201601 [2] - The company aims to complete the Phase III clinical research and new drug application for JJH201501 by the end of 2025, leveraging existing product channels for commercialization [2] - The company has established a professional R&D team of over 100 members and is focusing on innovative drug research, particularly first-class innovative drugs [2] Group 2: Future R&D Strategy - The company intends to enhance its R&D strategy by targeting major disease markets and utilizing a combination of in-house development, external collaborations, acquisitions, and product licensing to enrich its product pipeline [3] - The company is focusing on developing first-in-class antibody drugs, which carry high risks but could lead to revolutionary treatment breakthroughs [3] - The integration of artificial intelligence in drug development is seen as a new trend to improve efficiency and quality [4] Group 3: Overseas Business Expansion - The overseas business has become a focal point, with the company achieving good results in both domestic and international markets, particularly in the EU market for its albumin paclitaxel product [4] - The company plans to leverage its established overseas commercialization platform to introduce new products and drive sales, aiming for a 200% to 400% increase in overseas sales revenue by 2025 compared to 2023 [5] - The company will focus on high-tech barrier products in key markets and expedite the registration and market launch of introduced products [5] Group 4: Business Outlook - The company is committed to optimizing its product structure and enhancing operational efficiency while focusing on high-value-added product lines [6] - The company will continue to increase R&D investment and improve its management systems to ensure sustainable growth [6] - The company aims to implement an "AI + synthetic biology" strategy and pursue international development, leveraging digitalization and intelligence for high-quality, sustainable growth [7]